Clinical trial

The Impact of Oral Cannabis Administration and Co-Administration of Alcohol on Impairment

Name
IRB00290015
Description
This study will evaluate the individual and interactive effects of oral cannabis and alcohol on subjective and behavioral measures of impairment.
Trial arms
Trial start
2022-02-17
Estimated PCD
2025-05-01
Trial end
2025-05-01
Status
Recruiting
Phase
Early phase I
Treatment
Cannabis
Cannabis will be orally ingested via a brownie
Arms:
Placebo cannabis + high dose alcohol, Placebo cannabis + low dose alcohol, Placebo cannabis + placebo alcohol, high dose cannabis with low dose alcohol, high dose cannabis with placebo alcohol, low dose cannabis with low dose alcohol, low dose cannabis with placebo alcohol
Alcohol
Alcohol will be orally ingested via a flavored drink
Arms:
Placebo cannabis + high dose alcohol, Placebo cannabis + low dose alcohol, Placebo cannabis + placebo alcohol, high dose cannabis with low dose alcohol, high dose cannabis with placebo alcohol, low dose cannabis with low dose alcohol, low dose cannabis with placebo alcohol
Size
90
Primary endpoint
DRUID application global impairment score
7.5 hours
Correct Trials on Paced Auditory Serial Addition Task (PASAT)
7.5 hours
Correct Trials on the Digit Symbol Substitution Task (DSST)
7.5 hours
Cumulative score on Field Sobriety Tests
7.5 hours
Drug Effect Questionnaire (DEQ) - Feel Drug Effect
7.5 hours
Drug Effect Questionnaire - Feel High
7.5 hours
Drug Effect Questionnaire - Confidence to Drive
7.5 hours
Drug Effect Questionnaire - Willingness to Drive
7.5 hours
Biphasic alcohol effects scale (BAES) - Sedative Score
7.5 hours
Biphasic alcohol effects scale (BAES) - Stimulant Score
7.5 hours
Subjective high assessment scale (SHAS)
7.5 hours
Driving performance as assessed by standard deviation of lateral position (SDLP)
7.5 hours
Driving performance as assessed by composite drive score
7.5 hours
Eligibility criteria
Inclusion Criteria: 1. Have provided written informed consent 2. Be between the ages of 21 and 55 3. Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests 4. Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at each study visit. 5. Have a body mass index (BMI) in the range of 19 to 36 kg/m2 6. Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg 7. Have not donated blood in the prior 30 days. 8. Report at least 2 days of binge drinking in the past 90 days (greater than 4 or 5 drinks on a single occasion for women and men, respectively) 9. Report ≥ 1 use of cannabis in the past year 10. Provide negative urine test for illicit drug use (excluding THC) and negative breath alcohol test (0% BAC) at screening and before study sessions 11. Report at least 1 instance of simultaneous alcohol and use in the past year. Exclusion Criteria: 1. Psychoactive drug use (aside from cannabis, nicotine, alcohol, or caffeine) in past month 2. Current use of over-the-counter (OTC) drugs, supplements/vitamins, or prescription medications that, in the opinion of the investigator or medical staff, will impact the participant's safety 3. History of or current evidence of significant medical condition 4. Evidence of current psychiatric condition \[(MINI for Diagnostic and Statistical Manual (DSM)-V)\] 5. Meet criteria for severe alcohol use disorder (MINI for DSM-V) 6. Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar) score \> 9 7. Been in treatment previously for alcohol or cannabis use disorder 8. Use of cannabis, on average, more than 2 times/week over past 3 months 9. Liver function tests more than 2x normal range 10. Enrollment in another clinical trial or receiving of any drug as part of research within past 30 days 11. Shipley vocabulary score \<18 (corresponds to 5th grade reading level).
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'interventionModelDescription': 'All participants will complete all dose conditions (study arms) in a randomized order', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'DOUBLE', 'maskingDescription': 'Double-blind (Participant, Outcomes Assessor), placebo controlled, and double-dummy', 'whoMasked': ['PARTICIPANT', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 90, 'type': 'ESTIMATED'}}
Updated at
2024-03-19

1 organization

2 products

2 indications

Product
Alcohol
Product
Cannabis